Two-Day Program Sept. 29–30, 2021
|
view Or Purchase On-demand Content
Program registrants receive complimentary access to on-demand content.
On-demand content is available for purchase for those who did not register to attend the program. A discount is available for SITC Members. Renew your dues or become a SITC member today.
On-demand enduring materials are available as permitted by presenters.
Indicates this content is not available on-demand.
|
Wednesday, Sept. 29, 2021 *All times are Eastern Daylight Time.
|
Opening Remarks |
Time: |
10:00 – 10:10 a.m. EDT
|
Length:
|
10 minutes
|
Organizer:
|
Samir M. Hanash, MD, PhD – The University of Texas MD Anderson Cancer Center |
Session I: “Omics” Technologies and the Surfaceome
|
Time:
|
10:10 –11:40 a.m. EDT
|
Length:
|
90 minutes
|
Moderator:
|
Samir M. Hanash, MD, PhD – The University of Texas MD Anderson Cancer Center |
10:10 a.m.
|
Vaccinating against neoantigens induced in tumors and pathogen infected cells Eli Gilboa, PhD – University of Miami
|
10:40 a.m.
|
Development and engineering of human sialidase for degradation of immunosuppressive cell surface sialoglycans to treat cancer Li Peng, PhD – Palleon Pharmaceuticals
|
11:10 a.m.
|
Neoantigen Discovery and Targeting Robert D. Schreiber, PhD –Washington University School of Medicine
|
11:40 a.m.
|
Break
|
Session II: Tumor Neoantigens
|
Time:
|
11:50 a.m.– 1:20 p.m. EDT
|
Length:
|
90 minutes
|
Moderator:
|
Samir M. Hanash, MD, PhD – The University of Texas MD Anderson Cancer Center
|
11:50 a.m.
|
Canonical Neoantigens Beatriz M. Carreno, PhD – University of Pennsylvania
|
12:20 p.m.
|
Non-Canonical Tumor-Specific Antigens Claude Perreault, MD – University of Montreal
|
12:50 a.m.
|
RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets Yi Xing, PhD – Children's Hospital of Philadelphia
|
Break
|
Time:
|
1:20 –1:40 p.m. EDT
|
Session III: Oral Abstract Presentations
|
Time:
|
1:40 – 2:40 p.m. EDT
|
Length:
|
60 minutes
|
Moderator:
|
Avery D. Posey Jr., PhD – University of Pennsylvania School of Medicine
|
1:40 p.m.
|
Identification of novel, tumor specific pHLA targets recognized by TILs from CPI responders in a high-throughput, high-diversity pHLA library screening platform Hans-Peter Gerber, PhD – 3T Biosciences
|
1:55 p.m.
|
Protein citrullination as a source of cancer neoantigens Hiroyuki Katayama, PhD –The University of Texas MD Anderson Cancer Center (NO)
|
2:10 p.m.
|
Mapping the high-risk Multiple Myeloma cell surface proteome identifies T-cell inhibitory receptors for immune targeting Fabiana Perna, MD, PhD – Indiana University School of Medicine
|
2:25 p.m.
|
The extracellular vesicle surfaceome is enriched in tumor antigens and conveys an immune-signature in lung cancer Jody Vykoukal, PhD – The University of Texas MD Anderson Cancer Center
|
Keynote
|
Time:
|
2:40 – 3:15 p.m. EDT
|
Length:
|
35 minutes
|
2:40 p.m.
|
Keynote Carl H. June, PhD – University of Pennsylvania
|
Session IV: Extracellular Vesicles |
Time:
|
3:15 – 4:15 p.m. EDT
|
Length:
|
60 minutes
|
Moderator:
|
Avery D. Posey Jr., PhD – University of Pennsylvania School of Medicine
|
3:15 p.m.
|
Mining the Cancer Cell surfaceome Samir M. Hanash, MD, PhD – The University of Texas MD Anderson Cancer Center
|
3:45 p.m.
|
The Immunopeptidome of extracellular vesicles Simon J. Powis, PhD – University of St. Andrews
|
4:15 p.m.
|
Break
|
Session V: Post-Translational Modifications |
Time:
|
4:20 – 5:20 p.m. EDT
|
4:20 p.m.
|
A Genetic Approach to Display and Dissect the Cancer-Associated Truncated O-Glycoprotein Epitome Henrik Clausen, DDS, DSc – University of Copenhagen
|
4:50 p.m.
|
Tumor-specific Glycosylation and Antibody-Based Targeting Richard D. Cummings, PhD – Harvard Medical School
|
Closing Remarks
|
Time:
|
5:20 – 5:30 p.m. EDT
|
Length:
|
10 minutes |
Organizer:
|
Samir M. Hanash, MD, PhD – The University of Texas MD Anderson Cancer Center
|
5:30 p.m.
|
Adjourn
|